Treatment of brain tumour stem cells isolated from glioblastoma patients with BMP reduced their tumourigenic potential through inhibition of the proliferation capacity and increased glial differentiation [47] and proliferation arrest by BMPs has been shown also for MB [13], raising the possibility that small molecules acting as BMP agonists could be developed to be used therapeutically in MB patients. Here, CLN5 is linked to brain neoplasm.